Quote · Moonshots with Peter Diamandis
Anthropic Files $965B IPO, Trump Signs AI Executive Order, and ChatGPT Crosses 1B Users | EP #262
Where this was said
VRRV-102: One Shot That Could Cure Heart Disease
At 1:35:00 · chapter starts 1:33:35
A single CRISPR base-editing infusion permanently switches off PCSK9, cutting LDL 62% for 18+ months in Phase 1 trials. Wissner-Gross calls it Star Trek-level medicine. [1] — Peter Diamandis "VRRV-102 is a single gene-editing infusion that permanently switches off the PCSK9 gene, cutting LDL cholesterol 62% and sustaining results…" 1:33:30 [2] — Dr. Alexander Wissner-Gross "AI is going to cook math. AI is cooking math. AI has cooked math." 1:02:13
A single-infusion gene-editing therapy (VRRV-102) targeting the PCSK9 gene reduced LDL cholesterol by 62% and PCSK9 protein levels by 88% in a Phase 1 trial.
The LDL reduction from the VRRV-102 PCSK9 gene-editing therapy was sustained for up to 18 months in the Phase 1 trial — from a single infusion.
Even with a perfect AI algorithm, Dr. Wissner-Gross argues compute demand would still surge — Jevons Paradox style. Algorithmic improvements are currently absorbing half of all hardware gains. If they saturate, hardware pressure would only intensify.
